NASDAQ:EIGR
Eiger BioPharmaceuticals, Inc. Stock News
$1.73
+0 (+0%)
At Close: Apr 26, 2024
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturu
Daily Insider Ratings Round Up 1/30/20
06:57pm, Monday, 03'rd Feb 2020
Tables of the top insider purchases and sales filed with the SEC on 1/30/20, based on dollar value. Dollar values often do not equate with significance when it
Analysts' Downgrades for January, 28th (ABBV, ACHC, ALGN, AMAT, ARGKF, ARWR, ATRC, ATVI, BGNE, BPFH)
08:26am, Tuesday, 28'th Jan 2020
Analysts’ downgrades for Tuesday, January 28th: AbbVie (NYSE:ABBV) was downgraded by analysts at ValuEngine from a hold rating to a sell rating. Acadia Healthcare (NASDAQ:ACHC) was downgraded by ana
Top Insider Buys Highlight for the Week of Jan. 17
08:04pm, Sunday, 19'th Jan 2020
Insiders invest in JPMorgan, Simply Good Foods, Eiger BioPharmaceuticals and Geron Continue reading...
Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares
10:24am, Wednesday, 15'th Jan 2020
Whilst it may not be a huge deal, we thought it was good to see that the Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR...
Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
01:00pm, Tuesday, 07'th Jan 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare dis
Eiger Updates on 2019 Progress and 2020 Milestones Expected
01:00pm, Monday, 06'th Jan 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, t
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare di
Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
06:33am, Saturday, 07'th Dec 2019
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge
Eiger to Present at Jefferies 2019 London Healthcare Conference
01:00pm, Friday, 15'th Nov 2019
PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases
- 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve > 2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , .
Xconomy: Alder BioPharma’s Schatzman Steps Down as CEO by “Mutual Decision”
11:09pm, Tuesday, 20'th Mar 2018
Alder BioPharmaceuticals is now looking for a new chief executive, just as the company readies plans to file for FDA approval of its lead drug for
